Loading...
Market
Which major company partners with Baker's team for antivenom by end of 2025?
3
Resolution / Starting Odds
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Partnership announcements from pharmaceutical companies or research institutions
Story
AI-Designed Proteins Achieve 80-100% Survival Rates Against Snake Venom Toxins in Study by Nobel Laureate David Baker on January 15, 2025
Jan 15, 2025, 04:48 PM
Researchers have developed a groundbreaking snakebite treatment using artificial intelligence, marking a significant advancement in antivenom development. A study published on January 15, 2025, in the journal Nature details how AI-designed proteins can neutralize deadly snake venom toxins. Conducted by a team led by Nobel Laureate David Baker, the research demonstrated survival rates of 80-100% in mice subjected to lethal snake toxins. The study highlights the potential for faster, cheaper, and more effective treatment options for snakebites, which could transform the landscape of drug development and emergency medical responses to such incidents.
View original story
Similar markets
Pfizer • 25%
Johnson & Johnson • 25%
Sanofi • 25%
Other • 25%
Other • 25%
The Nature Conservancy • 25%
Conservation International • 25%
WWF • 25%
Other • 25%
Moderna • 25%
Johnson & Johnson • 25%
Pfizer • 25%
Other • 25%
Johnson & Johnson • 25%
Pfizer • 25%
Moderna • 25%
Sub-Saharan Africa • 25%
Other • 25%
South America • 25%
Southeast Asia • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
